| abstract |
The present invention provides a compound of formula (I) as an antagonist of a calcitonin gene related peptide receptor (“CGRP-receptor”): , A pharmaceutical composition containing the same, a method of identifying the same, a method of treatment using the same, and neural vasodilation, neurological inflammation, migraine and other headaches, burns, circulatory shock, climacteric facial flushing, It relates to use in therapeutics to treat airway inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD), and other medical conditions that can be treated with antagonists of CGRP-receptors. |